WXBMAIN WXB Futures(MAR5)
- 27.49
- -1.08-3.78%
WXB Futures(MAR5) News
Bull market sentiment? The WuXi group drives the Sector to explode, high position funds are still trapped, and Fund managers predict that the Innovative Drugs market will last throughout the year.
① The WuXi system has driven a significant rise in the pharmaceutical Sector, the Innovative Drugs bull has arrived; ② Feedback from fund investors: the Fund has rebounded, but has not returned to the original investment; ③ Investors are most concerned about whether the market can continue.
Is the CRO Concept "Return of the King"? WuXi AppTec aggressively attacks, leading stocks celebrate after performance!
Release the signal?!
Trending Industry Today: WUXI APPTEC Leads Gains In CRO Stocks
Express News | Hong Kong Indexes Rally, Blue-Chip Stocks Rise; Some Industry-Leading Stocks Surge. U.S. Listed Chinese Equities Trade Higher in Overnight Trading
Trending Industry Today: WUXI BIO Leads Gains In Biotechnology Stocks
Trending Industry Today: WUXI BIO Leads Gains In CRO Stocks
WuXi Biologics Included in S&P Global Sustainability Yearbook 2025
Ranking in top 1% of S&P Global CSA Score Inclusion in Global Yearbook for third consecutive year Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 11, 2025 /PRNewswire/
WuXi Biologics Included in S&P Global Sustainability Yearbook 2025
WUXI BIO has launched a new microbial expression platform EffiX to empower high-yield recombinant proteins and plasmids.
- EffiX aims to meet the market's demand for high-yield, stable, non-solvent-based E. coli expression systems, providing comprehensive solutions for the development and production of non-antibody recombinant proteins and plasmid DNA for Global clients. - EffiX can achieve high yields across various types of molecules, with non-antibody recombinant protein yields exceeding 15 grams per liter and plasmid DNA yields exceeding 1 gram per liter. Hangzhou, March 4, 2025 /PR Newswire/ -- A global leader in contract research, development, and manufacturing (CRDMO) services.
WuXi Biologics Launches EffiX Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
Trending Industry Today: PHARMARON Leads Losses In CRO Stocks
WUXI BIO has once again passed the Japan PMDA GMP inspection, accumulating 42 passes through Global Pharmaceutical regulatory inspections.
WUXI BIO announced on February 27, 2025, in Wuxi / PR Newswire / -- that the company’s biopharmaceutical raw material production plants (MFG2 and MFG5) at its Wuxi base have again passed the GMP inspection by the Japan Pharmaceutical and Medical Devices Agency (PMDA). The company achieved a zero-defect result in this on-site inspection covering facility quality systems and the entire production process, showcasing its outstanding capability to meet Global regulatory requirements. So far, WUXI BIO has successfully accumulated.
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
Is Trump’s risk disturbing the market? Pharmaceutical stocks have suddenly changed, and the WuXi group has collapsed entirely!
Under the AI boom, the Biomedical and AI Medical stocks have been running wild this year.
Trending Industry Today: WUXI BIO Leads Losses In CRO Stocks
The CRO Sector is under pressure, WUXI BIO (02269) fell 6.73% as it is rumored that the USA intends to restrict investments by Chinese enterprises in several strategic areas.
Kingwu Financial News | The CRO Sector is under pressure, WUXI BIO (02269) fell by 6.73%, WUXI APPTEC (02359) fell by 5.57%, VIVA BIOTECH (01873) fell by 3.77%, TIGERMED (03347) fell by 3.5%, PHARMARON (03759) fell by 3.12%. According to media reports citing anonymous USA officials, President Trump signed an order directing the Treasury Department's Committee on Foreign Investment in the USA (CFIUS) to continue restricting Chinese companies from making investments in several strategic sectors in the USA. Reports indicate that the purpose of the memorandum is to ensure USA National Security while requiring
WUXI BIO: DATE OF BOARD MEETING
Hong Kong stocks are moving | CRO Concept stocks continue to rise, VIVA BIOTECH (01873) is up nearly 10%, PHARMARON (03759) is up over 9%.
CRO Concept stocks continue to rise. As of the time of writing, VIVA BIOTECH (01873) is up 9.72%, trading at 1.58 Hong Kong dollars; PHARMARON (03759) is up 9.43%, trading at 19.04 Hong Kong dollars; TIGERMED (03347) is up 7.45%, trading at 38.2 Hong Kong dollars.
Trending Industry Today: ZAI LAB Leads Gains In Biotechnology Stocks
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$30.59 From HK$19.30, Keeps at Buy